Rui Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rui Mao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anamika Gupta
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
6 shared publications - Bingwei Ye
Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, Georgia
6 shared publications - Han-Fei Ding
University of Alabama at Birmingham 1 Department of Pathology, Heersink School of Medicine Birmingham, Alabama
6 shared publications - Jane Ding
University of Alabama at Birmingham 1 Department of Pathology, Heersink School of Medicine Birmingham, Alabama
6 shared publications - Mohit Bansal
University of Alabama at Birmingham 1 Department of Pathology, Heersink School of Medicine Birmingham, Alabama
6 shared publications - Sunil Sudarshan
Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA
6 shared publications
Latest Publications
- Open Access
Fast receptor-antigen dissociation kinetics promote CAR-T cell tumor infiltration, functional fitness, and antitumor efficacy in solid tumors
Background: CAR-T cells have shown limited efficacy against solid tumors, where they face two major challenges: restricted tumor infiltration and sustained intensive engagement that drive them to exhaustion. Conventional CAR design has largely emphasized high-affinity interactions with slow dissociation, further limiting tumor infiltration and exacerbating exhaustion and dysfunction. We hypothesize that most current CARs are kinetically over-stabilized for solid tumors and that a fast-on/fast-off, “ cheek-kiss ” mode of engagement permits transient CAR–antigen disengagement, thereby facilitating tumor infiltration and preserving CAR-T cell fitness in tumor mass. Methods: We identified two monoclonal antibodies targeting the same epitope of epidermal growth factor receptor with comparable k on but distinct k off rates: cetuximab (Cet) and its humanized derivative H1. CAR-T cells incorporating these binders were evaluated in vitro and in vivo . Large, established human tumor xenografts were treated with low-dose CAR-T cells in NSG mice to model conditions of limited T cell availability and sustained tumor antigen exposure. Results: Cet and H1 exhibited comparable k on but markedly different k off rates, with H1 displaying fast-off kinetics with approximately 18-fold shorter binding dwell time. As CARs, H1 showed reduced antigen occupancy and less stable tumor-T cell engagement than Cet. Despite comparable in vitro cytotoxicity, H1 CAR-T cells accumulated more efficiently following tumor stimulation. At high doses, both CAR-T cell products eradicated established tumors. Under low-dose conditions, however, H1 CAR-T cells exhibited superior expansion, persistence, tumor infiltration, and antitumor efficacy, whereas Cet CAR-T cells showed limited expansion and only transient tumor control. Cet CAR-T cells progressively downregulated surface CAR expression, increased PD-1 expression, and exhibited reduced tumor infiltration and impaired functional recovery. In contrast, H1 CAR-T cells preserved surface CAR expression, exhibited greater tumor infiltration, maintained a less exhausted, more central memory-like phenotype, and retained effector function. Conclusion: Fast-on/fast-off binding kinetics enhance CAR-T tumor infiltration, expansion, persistence, and functional fitness, resulting in improved control of established solid tumors. The data provides a rationale for shifting CAR design from affinity optimization toward kinetic optimization to improve the efficacy and safety of CAR-T therapy for solid tumors. WHAT IS ALREADY KNOWN ON THIS TOPIC: CAR design has largely focused on antigen-binding affinity, whereas the contribution of binding kinetics, particularly the dissociation rate, to CAR-T cell function, expansion, persistence, tumor infiltration, and antitumor efficacy remains poorly defined. WHAT THIS STUDY ADDS: In this study, we found that, compared with slow-off binding, fast-off kinetics enhance CAR-T cell tumor infiltration, expansion, persistence, and functional fitness in tumor-bearing mice, revealing previously underappreciated effects of antigen-binding kinetics on CAR-T cell tumor infiltration and performance in solid tumors. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY: This study provides a rationale for incorporating antigen-binding kinetics into CAR design and optimization. The TCR-inspired fast-on/fast-off antigen engagement may help CAR T cells maintain fitness during sustained antigen exposure and thereby improve their infiltration, persistence, and antitumor activity in solid tumors.
Open AccessFast receptor-antigen dissociation kinetics promote CAR-T cell tumor infiltration, functional fitness, and antitumor efficacy in solid tumors
Background: CAR-T cells have shown limited efficacy against solid tumors, where they face two major challenges: restricted tumor infiltration and sustained intensive engagement that drive them to exhaustion. Conventional CAR design has largely emphasized high-affinity interactions with slow dissociation, further limiting tumor infiltration and exacerbating exhaustion and dysfunction. We hypothesize that most current CARs are kinetically over-stabilized for solid tumors and that a fast-on/fast-off, “ cheek-kiss ” mode of engagement permits transient CAR–antigen disengagement, thereby facilitating tumor infiltration and preserving CAR-T cell fitness in tumor mass. Methods: We identified two monoclonal antibodies targeting the same epitope of epidermal growth factor receptor with comparable k on but distinct k off rates: cetuximab (Cet) and its humanized derivative H1. CAR-T cells incorporating these binders were evaluated in vitro and in vivo . Large, established human tumor xenografts were treated with low-dose CAR-T cells in NSG mice to model conditions of limited T cell availability and sustained tumor antigen exposure. Results: Cet and H1 exhibited comparable k on but markedly different k off rates, with H1 displaying fast-off kinetics with approximately 18-fold shorter binding dwell time. As CARs, H1 showed reduced antigen occupancy and less stable tumor-T cell engagement than Cet. Despite comparable in vitro cytotoxicity, H1 CAR-T cells accumulated more efficiently following tumor stimulation. At high doses, both CAR-T cell products eradicated established tumors. Under low-dose conditions, however, H1 CAR-T cells exhibited superior expansion, persistence, tumor infiltration, and antitumor efficacy, whereas Cet CAR-T cells showed limited expansion and only transient tumor control. Cet CAR-T cells progressively downregulated surface CAR expression, increased PD-1 expression, and exhibited reduced tumor infiltration and impaired functional recovery. In contrast, H1 CAR-T cells preserved surface CAR expression, exhibited greater tumor infiltration, maintained a less exhausted, more central memory-like phenotype, and retained effector function. Conclusion: Fast-on/fast-off binding kinetics enhance CAR-T tumor infiltration, expansion, persistence, and functional fitness, resulting in improved control of established solid tumors. The data provides a rationale for shifting CAR design from affinity optimization toward kinetic optimization to improve the efficacy and safety of CAR-T therapy for solid tumors. WHAT IS ALREADY KNOWN ON THIS TOPIC: CAR design has largely focused on antigen-binding affinity, whereas the contribution of binding kinetics, particularly the dissociation rate, to CAR-T cell function, expansion, persistence, tumor infiltration, and antitumor efficacy remains poorly defined. WHAT THIS STUDY ADDS: In this study, we found that, compared with slow-off binding, fast-off kinetics enhance CAR-T cell tumor infiltration, expansion, persistence, and functional fitness in tumor-bearing mice, revealing previously underappreciated effects of antigen-binding kinetics on CAR-T cell tumor infiltration and performance in solid tumors. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY: This study provides a rationale for incorporating antigen-binding kinetics into CAR design and optimization. The TCR-inspired fast-on/fast-off antigen engagement may help CAR T cells maintain fitness during sustained antigen exposure and thereby improve their infiltration, persistence, and antitumor activity in solid tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Table S1. primers and oligonucleotides. Table S2. Microarray gene expression profiling (shPUS7-33 vs shGFP). Table S3. Functional annotation of PUS7 knockdown-responsive genes. Table S4. 13C-glucose metabolic flux analysis. Table S5. 13C-15N-glutamine metabolic flux analysis. Table S6. Nanopore RNA seq - MCTS1 mRNA Y modification. Table S7. Proteomic analysis of proteins downregulated by PUS7 knockdown in BE(2)-C cells. Table S8. Polysome enrichment of transcripts with higher levels of pseudouridylation. Table S9. Nanopore RNA seq - ATF4 mRNA Y modification
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Table S1. primers and oligonucleotides. Table S2. Microarray gene expression profiling (shPUS7-33 vs shGFP). Table S3. Functional annotation of PUS7 knockdown-responsive genes. Table S4. 13C-glucose metabolic flux analysis. Table S5. 13C-15N-glutamine metabolic flux analysis. Table S6. Nanopore RNA seq - MCTS1 mRNA Y modification. Table S7. Proteomic analysis of proteins downregulated by PUS7 knockdown in BE(2)-C cells. Table S8. Polysome enrichment of transcripts with higher levels of pseudouridylation. Table S9. Nanopore RNA seq - ATF4 mRNA Y modification
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Figure S1. PUS7 is a direct transcriptional target of MYC oncoproteins. Figure S2. High PUS7 expression is associated with poor prognosis and is required for the proliferation and tumorigenicity MYC-driven cancer cells. Figure S3. Functional annotation of PUS7 target genes. Figure S4. PUS7 sustains amino acid biosynthesis and adaptive stress responses. Figure S5. PUS7 protects cells from MYCN-induced cellular stress by enabling ATF4-mediated adaptive responses. Figure S6. PUS7 targets MCTS1 to sustain ATF4 mRNA translation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Figure S1. PUS7 is a direct transcriptional target of MYC oncoproteins. Figure S2. High PUS7 expression is associated with poor prognosis and is required for the proliferation and tumorigenicity MYC-driven cancer cells. Figure S3. Functional annotation of PUS7 target genes. Figure S4. PUS7 sustains amino acid biosynthesis and adaptive stress responses. Figure S5. PUS7 protects cells from MYCN-induced cellular stress by enabling ATF4-mediated adaptive responses. Figure S6. PUS7 targets MCTS1 to sustain ATF4 mRNA translation.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Figure S1. PUS7 is a direct transcriptional target of MYC oncoproteins. Figure S2. High PUS7 expression is associated with poor prognosis and is required for the proliferation and tumorigenicity MYC-driven cancer cells. Figure S3. Functional annotation of PUS7 target genes. Figure S4. PUS7 sustains amino acid biosynthesis and adaptive stress responses. Figure S5. PUS7 protects cells from MYCN-induced cellular stress by enabling ATF4-mediated adaptive responses. Figure S6. PUS7 targets MCTS1 to sustain ATF4 mRNA translation.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Figure S1. PUS7 is a direct transcriptional target of MYC oncoproteins. Figure S2. High PUS7 expression is associated with poor prognosis and is required for the proliferation and tumorigenicity MYC-driven cancer cells. Figure S3. Functional annotation of PUS7 target genes. Figure S4. PUS7 sustains amino acid biosynthesis and adaptive stress responses. Figure S5. PUS7 protects cells from MYCN-induced cellular stress by enabling ATF4-mediated adaptive responses. Figure S6. PUS7 targets MCTS1 to sustain ATF4 mRNA translation.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Table S1. primers and oligonucleotides. Table S2. Microarray gene expression profiling (shPUS7-33 vs shGFP). Table S3. Functional annotation of PUS7 knockdown-responsive genes. Table S4. 13C-glucose metabolic flux analysis. Table S5. 13C-15N-glutamine metabolic flux analysis. Table S6. Nanopore RNA seq - MCTS1 mRNA Y modification. Table S7. Proteomic analysis of proteins downregulated by PUS7 knockdown in BE(2)-C cells. Table S8. Polysome enrichment of transcripts with higher levels of pseudouridylation. Table S9. Nanopore RNA seq - ATF4 mRNA Y modification
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Table S1. primers and oligonucleotides. Table S2. Microarray gene expression profiling (shPUS7-33 vs shGFP). Table S3. Functional annotation of PUS7 knockdown-responsive genes. Table S4. 13C-glucose metabolic flux analysis. Table S5. 13C-15N-glutamine metabolic flux analysis. Table S6. Nanopore RNA seq - MCTS1 mRNA Y modification. Table S7. Proteomic analysis of proteins downregulated by PUS7 knockdown in BE(2)-C cells. Table S8. Polysome enrichment of transcripts with higher levels of pseudouridylation. Table S9. Nanopore RNA seq - ATF4 mRNA Y modification
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Data from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Pseudouridylation is a common RNA modification that is catalyzed by the family of pseudouridine synthases (PUS). Pseudouridylation can increase RNA stability and rigidity, thereby impacting RNA splicing, processing, and translation. Given that RNA metabolism is frequently altered in cancer, pseudouridylation may be a functionally important process in tumor biology. Here, we show that the MYC family of oncoproteins transcriptionally upregulates PUS7 expression during cancer development. PUS7 is essential for the growth and survival of MYC-driven cancer cells and xenografts by promoting adaptive stress responses and amino acid biosynthesis and import. ATF4, a master regulator of stress responses and cellular metabolism, was identified as a key downstream mediator of PUS7 functional activity. Induction of ATF4 by MYC oncoproteins and cellular stress required PUS7, and ATF4 overexpression overcame the growth inhibition caused by PUS7 deficiency. Mechanistically, PUS7 induced pseudouridylation of MCTS1 mRNA, which enhanced its translation. MCTS1, a noncanonical translation initiation factor, drove stress-induced ATF4 protein expression. A PUS7 consensus pseudouridylation site in the 3′ untranslated region of ATF4 mRNA was crucial for the induction of ATF4 by cellular stress. These findings unveil an MYC-activated mRNA pseudouridylation program that mitigates cellular stress induced by MYC stimulation of proliferation and biomass production, suggesting that targeting PUS7 could be a therapeutic strategy selectively against MYC-driven cancers.Significance: Oncogene activation of mRNA pseudouridylation is a mechanism that facilitates metabolic reprogramming and adaptive responses to overcome cellular stress during cancer development.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Pseudouridylation is a common RNA modification that is catalyzed by the family of pseudouridine synthases (PUS). Pseudouridylation can increase RNA stability and rigidity, thereby impacting RNA splicing, processing, and translation. Given that RNA metabolism is frequently altered in cancer, pseudouridylation may be a functionally important process in tumor biology. Here, we show that the MYC family of oncoproteins transcriptionally upregulates PUS7 expression during cancer development. PUS7 is essential for the growth and survival of MYC-driven cancer cells and xenografts by promoting adaptive stress responses and amino acid biosynthesis and import. ATF4, a master regulator of stress responses and cellular metabolism, was identified as a key downstream mediator of PUS7 functional activity. Induction of ATF4 by MYC oncoproteins and cellular stress required PUS7, and ATF4 overexpression overcame the growth inhibition caused by PUS7 deficiency. Mechanistically, PUS7 induced pseudouridylation of MCTS1 mRNA, which enhanced its translation. MCTS1, a noncanonical translation initiation factor, drove stress-induced ATF4 protein expression. A PUS7 consensus pseudouridylation site in the 3′ untranslated region of ATF4 mRNA was crucial for the induction of ATF4 by cellular stress. These findings unveil an MYC-activated mRNA pseudouridylation program that mitigates cellular stress induced by MYC stimulation of proliferation and biomass production, suggesting that targeting PUS7 could be a therapeutic strategy selectively against MYC-driven cancers.Significance: Oncogene activation of mRNA pseudouridylation is a mechanism that facilitates metabolic reprogramming and adaptive responses to overcome cellular stress during cancer development.
- Open Access
- 6 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (23) , 4031-4048
MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Pseudouridylation is a common RNA modification that is catalyzed by the family of pseudouridine synthases (PUS). Pseudouridylation can increase RNA stability and rigidity, thereby impacting RNA splicing, processing, and translation. Given that RNA metabolism is frequently altered in cancer, pseudouridylation may be a functionally important process in tumor biology. Here, we show that the MYC family of oncoproteins transcriptionally upregulates PUS7 expression during cancer development. PUS7 is essential for the growth and survival of MYC-driven cancer cells and xenografts by promoting adaptive stress responses and amino acid biosynthesis and import. ATF4, a master regulator of stress responses and cellular metabolism, was identified as a key downstream mediator of PUS7 functional activity. Induction of ATF4 by MYC oncoproteins and cellular stress required PUS7, and ATF4 overexpression overcame the growth inhibition caused by PUS7 deficiency. Mechanistically, PUS7 induced pseudouridylation of MCTS1 mRNA, which enhanced its translation. MCTS1, a noncanonical translation initiation factor, drove stress-induced ATF4 protein expression. A PUS7 consensus pseudouridylation site in the 3′ untranslated region of ATF4 mRNA was crucial for the induction of ATF4 by cellular stress. These findings unveil an MYC-activated mRNA pseudouridylation program that mitigates cellular stress induced by MYC stimulation of proliferation and biomass production, suggesting that targeting PUS7 could be a therapeutic strategy selectively against MYC-driven cancers. Significance: Oncogene activation of mRNA pseudouridylation is a mechanism that facilitates metabolic reprogramming and adaptive responses to overcome cellular stress during cancer development.
- 6 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (23) , 4031-4048
Open AccessMYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
Pseudouridylation is a common RNA modification that is catalyzed by the family of pseudouridine synthases (PUS). Pseudouridylation can increase RNA stability and rigidity, thereby impacting RNA splicing, processing, and translation. Given that RNA metabolism is frequently altered in cancer, pseudouridylation may be a functionally important process in tumor biology. Here, we show that the MYC family of oncoproteins transcriptionally upregulates PUS7 expression during cancer development. PUS7 is essential for the growth and survival of MYC-driven cancer cells and xenografts by promoting adaptive stress responses and amino acid biosynthesis and import. ATF4, a master regulator of stress responses and cellular metabolism, was identified as a key downstream mediator of PUS7 functional activity. Induction of ATF4 by MYC oncoproteins and cellular stress required PUS7, and ATF4 overexpression overcame the growth inhibition caused by PUS7 deficiency. Mechanistically, PUS7 induced pseudouridylation of MCTS1 mRNA, which enhanced its translation. MCTS1, a noncanonical translation initiation factor, drove stress-induced ATF4 protein expression. A PUS7 consensus pseudouridylation site in the 3′ untranslated region of ATF4 mRNA was crucial for the induction of ATF4 by cellular stress. These findings unveil an MYC-activated mRNA pseudouridylation program that mitigates cellular stress induced by MYC stimulation of proliferation and biomass production, suggesting that targeting PUS7 could be a therapeutic strategy selectively against MYC-driven cancers. Significance: Oncogene activation of mRNA pseudouridylation is a mechanism that facilitates metabolic reprogramming and adaptive responses to overcome cellular stress during cancer development.